zinc finger protein 703 | |
---|---|
Identifiers | |
Symbol | ZNF703 |
NCBI gene | 80139 |
HGNC | 25883 |
RefSeq | NM_025069 |
Other data | |
Locus | Chr. 8 p12 |
ZNF703 is a gene which has been linked with the development of breast cancers. [5] [6] [7] ZNF703 is contained within the NET/N1z family responsible for regulation of transcription essential for developmental growth especially in the hindbrain. [8] Normal functions performed by ZNF703 include adhesion, movement and proliferation of cells. [8] ZNF703 directly accumulates histone deacetylases at gene promoter regions but does not bind to functional DNA. [9]
Following research by scientists at Cancer Research UK, it was the first oncogene discovery in the past six years. [6]
ZNF703 is a part of 8p12 telomeric amplicon that is associated with Luminal B breast cancer. Recently, ZNF703 is identified as the driver of 8p12 locus amplification. [10]
Patients diagnosed with luminal B cancer caused by ZNF703 typically have lower recovery and survival rates than other cancer types. [11]
Drug resistance of ZNF703 has been displayed when patients are treated using anti-cancer drug Tamoxifen. [12]
Researchers discovered the carcinogenic nature of ZNF703 in 2011 while conducting research on the classification and resistance of various oncogenes. [8] Researchers attempted to discern factors associated with various cancer types through observation of the oncogenic mechanism on a molecular scale. [8] The luminal B cancer pathway exhibited an amplification of 5 different genomic areas including the chromosome region 8p12. [8] Amplification of region 8p12 occurred through transcriptional regulation of ZNF703. [8]
ZNF703 is located on human chromosome 8 at the short arm region commonly named chromosome region 8p12. [5] Tumors generated by ZNF703 have shown loss in size beginning at the telomere and ending at 8p12 while the 8p12-11 region has increased size. [13] A fluctuation between increase and decrease is present along the 8p12-8p21 boundary region of the chromosome. [13] A pattern has been found that involves three similar regions of disrupted growth and four regions of enhanced growth starting from the telomere and ending at the centromere. [13]
The ZNF703 gene generally plays an active role in luminal B tumor cells contained in mammary ducts. [5] Typically, ZNF703 expression is greater when the tumors are estrogen receptor positive as opposed to estrogen receptor negative. [5] ZNF703 is co-expressed in a nuclear complex containing genes DCAF7, NCRO2 and PHB2. [5] ZNF703 generates a nuclear protein responsible for oestrogen receptor associated protein repression. [5] Gene expression of stem cells are triggered when the ZNF703 gene becomes overexpressed in the complex. [5] As a result, both regular cells and cancer stem cell abundance increases rapidly. [5] ZNF703 overexpression also causes primary and secondary tumorsphere development alongside amplified production of CD49F- positive cells associated with colon cancer. [5]
ZNF703 also experiences target regulation of cancer cells through the transcription of RNA SPRY4-It1. [14] RNA SPRY4-IT1 is a non-coding gene responsible for preventing apoptosis and generating large tumors. [14]
Researchers recently established a link between the trigger gene ZNF703 and Akt/mTOR pathway activation involved in the cellular cycle resulting in lung tumor formation. [15]
The lifespan of individuals with colorectal cancer and luminal cancer have different prognosis depending on the amount of expression of the ZNF703 gene. [11] Low amounts of transcription of ZNF703 usually leads to a healthier prognosis than individuals experiencing higher levels of transcription of the oncogene. [11] ZNF703 is a target for therapeutic medicines since survival rates increase as transcription rates decrease. [11]
The drug Tamoxifen is a commonly administered drug used to treat luminal cancers in patients. [12] Half of patients treated with Tamoxifen are resistant to the drug. [12] Overexpression of ZNF703 has been linked to Tamoxifen resistance. [12] As transcription of the ZNF703 gene reaches substantial levels, instead of blocking cell proliferation, Tamoxifen is found to increase cancer cell division. [12] Tamoxifen can only be given at low dosages and patients are monitored daily in order to avoid tumor growth. [12]
Receptor tyrosine-protein kinase erbB-2 is a protein that normally resides in the membranes of cells and is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene originally isolated from the avian genome. The human protein is also frequently referred to as HER2 or CD340.
N-myc proto-oncogene protein also known as N-Myc or basic helix-loop-helix protein 37 (bHLHe37), is a protein that in humans is encoded by the MYCN gene.
Signal transducer CD24 also known as cluster of differentiation 24 or heat stable antigen CD24 (HSA) is a protein that in humans is encoded by the CD24 gene. CD24 is a cell adhesion molecule.
Transcription factor Jun is a protein that in humans is encoded by the JUN gene. c-Jun, in combination with protein c-Fos, forms the AP-1 early response transcription factor. It was first identified as the Fos-binding protein p39 and only later rediscovered as the product of the JUN gene. c-jun was the first oncogenic transcription factor discovered. The proto-oncogene c-Jun is the cellular homolog of the viral oncoprotein v-jun. The viral homolog v-jun was discovered in avian sarcoma virus 17 and was named for ju-nana, the Japanese word for 17. The human JUN encodes a protein that is highly similar to the viral protein, which interacts directly with specific target DNA sequences to regulate gene expression. This gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies.
The nuclear receptor coactivator 3 also known as NCOA3 is a protein that, in humans, is encoded by the NCOA3 gene. NCOA3 is also frequently called 'amplified in breast 1' (AIB1), steroid receptor coactivator-3 (SRC-3), or thyroid hormone receptor activator molecule 1 (TRAM-1).
Cyclin D1 is a protein that in humans is encoded by the CCND1 gene.
Homeobox protein Hox-A9 is a protein that in humans is encoded by the HOXA9 gene.
ETS translocation variant 4 (ETV4), also known as polyoma enhancer activator 3 (PEA3), is a member of the PEA3 subfamily of Ets transcription factors.
SRY -box 2, also known as SOX2, is a transcription factor that is essential for maintaining self-renewal, or pluripotency, of undifferentiated embryonic stem cells. Sox2 has a critical role in maintenance of embryonic and neural stem cells.
Proto-oncogene tyrosine-protein kinase Src, also known as proto-oncogene c-Src, or simply c-Src, is a non-receptor tyrosine kinase protein that in humans is encoded by the SRC gene. It belongs to a family of Src family kinases and is similar to the v-Src gene of Rous sarcoma virus. It includes an SH2 domain, an SH3 domain and a tyrosine kinase domain. Two transcript variants encoding the same protein have been found for this gene.
The basal-like carcinoma is a recently proposed subtype of breast cancer defined by its gene expression and protein expression profile.
Upstream stimulatory factor 1 is a protein that in humans is encoded by the USF1 gene.
Forkhead box protein M1 is a protein that in humans is encoded by the FOXM1 gene. The protein encoded by this gene is a member of the FOX family of transcription factors. Its potential as a target for future cancer treatments led to it being designated the 2010 Molecule of the Year.
Anterior gradient protein 2 homolog (AGR-2), also known as secreted cement gland protein XAG-2 homolog, is a protein that in humans is encoded by the AGR2 gene. Anterior gradient homolog 2 was originally discovered in Xenopus laevis. In Xenopus AGR2 plays a role in cement gland differentiation, but in human cancer cell lines high levels of AGR2 correlate with downregulation of the p53 response, cell migration, and cell transformation. However, there have been other observations that AGR2 can repress growth and proliferation.
ID4 is a protein coding gene. In humans, it encodes for the protein known as DNA-binding protein inhibitor ID-4. This protein is known to be involved in the regulation of many cellular processes during both prenatal development and tumorigenesis. This is inclusive of embryonic cellular growth, senescence, cellular differentiation, apoptosis, and as an oncogene in angiogenesis.
The LBH gene is a highly conserved human gene that produces the LBH protein, a transcription co-factor in the Wnt/β-catenin pathway. Upon transcriptional activation of β-catenin, LBH goes on to act as a regulator of cell proliferation and differentiation through multiple transcriptional targets. The gene is located on the p arm of chromosome 2 and is roughly 28 kb long. Current ongoing studies are examining its role in developmental and oncological settings.
Breast carcinoma amplified sequence 3, also known as BCAS3, is a protein which in humans is encoded by the BCAS3 gene. BCAS3 is a gene that is amplified and overexpressed in breast cancer cells.
Pvt1 oncogene, also known as PVT1 or Plasmacytoma Variant Translocation 1 is a long non-coding RNA gene. In mice, this gene was identified as a breakpoint site in chromosome 6;15 translocations. These translocations are associated with murine plasmacytomas. The equivalent translocation in humans is t(2;8), which is associated with a rare variant of Burkitt's lymphoma. In rats, this breakpoint was shown to be a common site of proviral integration in retrovirally induced T lymphomas. Transcription of PVT1 is regulated by Myc.
Transcription factor AP-2 gamma also known as AP2-gamma is a protein that in humans is encoded by the TFAP2C gene. AP2-gamma is a member of the activating protein 2 family of transcription factors.
Endocrine therapy is a common treatment for estrogen receptor positive breast cancer. However, resistance to this therapy can develop, leading to relapse and progression of disease. This highlights the need for new strategies to combat this resistance.